The role of digitalis in the treatment of heart failure

Coronary Artery Disease

Volumn 10, Issue 6, 1999, Pages 353-360

  Demers, Catherine ^a   McKelvie, Robert S ^a,b   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HHSC General Division   (Canada)

Author keywords

Cardiac glycosides; Clinical trials; Heart failure therapy; Inotrope

Indexed keywords

CAPTOPRIL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IBOPAMINE; LISINOPRIL; MILRINONE; NEUROHORMONE; PLACEBO; QUINAPRIL; RAMIPRIL; XAMOTEROL;

ADVERSE DRUG REACTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EXERCISE TOLERANCE; HEART EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE BLIND PROCEDURE;

EID: 0032872020     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199909000-00002     Document Type: Review

References (29)

1. Kaye DM, Kelly RA, Smith TW. Cardiac glycosides. In Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJS (editors) Heart Failure. New York; Churchill Livingstone; 1997. pp. 649-667.
2. Guyatt GH, Sullivan MJJ, Fallen EL, Tihal H, Rideout E, Halcrow S, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1988; 61:371-375.
3. The Captopril-Digoxin MultiCenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988; 259:539-544. In this study, digoxin did not improve exercise time significantly but LVEF was significantly improved by 4.4% compared with baseline.
4. Beaune J, for the Enalapril Versus Digoxin French Multicenter Study Group. Comparison of enalapril versus digoxin for congestive heart failure. Am J Cardiol 1989; 63:22D-25D.
5. Davies RF, Beanlands DS, Nadeau C, Phaneuf D, Morris A, Arnold JM, et al. Enalapril versus digoxin in patients with congestive heart failure: a multicenter study. J Am Coll Cardiol 1991; 18:1602-1609. Maximal exercise capacity was significantly improved in the enalapril and digoxin groups (P< 0.001) after 4 and 14 weeks of treatment, compared with baseline, with no significant difference being observed between treatment.
6. Arnold SB, Byrd RC, Meister W, Melmon K, Cheitlin MD, Bristow JD, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med 1980; 303:1443-1448.
7. Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 1989; 13:134-142.
8. Van Veldhuisen DJ, Man in't Veld AJ, Dunselman PHJM, Lok DJA, Dohmen HJM, Pootermans JC, et al. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993; 22:1564-1573. After 6 months, digoxin but not ibopamine significantly increased exercise time (P=0.008) compared with placebo. Digoxin and ibopamine significantly decreased plasma levels of norepinephrine compared with placebo.
9. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525-533. In this large, randomized trial, digoxin did not decrease mortality (relative risk 0.99, P =0.80) compared with placebo in patients treated with ACE inhibitors and diuretics but fewer patients were hospitalized for CHF in the digoxin group (relative risk 0.72, P< 0.001). This study provides strong evidence for the safety of digoxin in the treatment of CHF and its effect in decreasing hospitalizations.
10. Dobbs SM, Kenyon WI, Dobbs RJ. Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. BMJ 1977; 1:749-752.
11. Lee DCS, Johnson RA, Bingham JB, Leahy M, Dinsmore RE, Goroll AH, et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med 1982; 306:699-705. This study demonstrated an improvement in heart failure score in patients treated with digoxin.
12. Fleg JL, Gottlieb SH, Lakatta EG. Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm. Am J Med 1982; 73:244-250.
13. Taggart AJ, Johnston GD, McDevitt DG. Digoxin withdrawal after cardiac failure in patients with sinus rhythm. J Cardiovasc Pharmacol 1983; 5:229-234.
14. Pugh SE, White NJ, Aronson JK, Grahame-Smith DG, Bloomfield JG. Clinical, haemodynamic, and pharmacological effects of withdrawal and reintroduction of digoxin in patients with heart failure in sinus rhythm after long term treatment. Br Heart J 1989; 61:529-539.
15. Fleg JL, Rothfeld B, Gottlieb SH. Effect of maintenance digoxin therapy on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: a randomized, placebo-controlled, crossover trial. J Am Coll Cardiol 1991; 17:743-751.
16. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993; 22:955-962. Digoxin withdrawal worsened maximal exercise capacity (P= 0.003) and increased incidence of treatment failure (P= 0.039), compared with patients who were treated with digoxin.
17. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993; 329:1-7. Patients withdrawn from digoxin therapy in this study had an increased risk of worsening CHF (relative risk 5.9, 95% confidence interval 2.1-17.2). Maximal exercise tolerance, submaximal exercise endurance, and NYHA class deteriorated in the digoxin withdrawal group compared with those receiving digoxin.
18. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-1435.
19. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
20. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-310.
21. Alicandri C, Fariello R, Boni E, Zaninelli A, Castellano M, Beschi M, et al. Captopril versus digoxin in mild-moderate chronic heart failure: a crossover study. J Cardiovasc Pharmacol 1987; 9 (suppl 2):S61 -S67.
22. Kromer EP, Elsner D, Riegger GAJ. Digoxin, converting-enzyme inhibition (quinapril), and the combination in patients with congestive heart failure functional class II and sinus rhythm. J Cardiovasc Pharmacol 1990; 16:9-14.
23. Kholeif MA, Pringle S, Kesson E, Murray G, Kennedy JA, Lorimer AR, et al. A comparison of the efficacy and safety of ramipril and digoxin added to maintenance diuretic treatment in patients with chronic heart failure. J Cardiovasc Pharmacol 1991; 18 (suppl 2):S180-S183.
24. Herlitz J, for the Lisinopril-Digoxin Study Group. Comparison of lisinopril versus digoxin for congestive heart failure during maintenance diuretic therapy. Am J Cardiol 1992; 70:84C-90C. Lisinopril and digoxin were shown to improve exercise tolerance 6 weeks from baseline, but there was no difference between treatment groups.
25. Just H, Drexler H, Taylor SH, Siegrist J, Schulgen G, Schumacher M, for the CADS study group. Captopril versus digoxin in patients with coronary artery disease and mild heart failure. Herz 1993; 18:436-443.
26. Heck I, Luderitz B, Muller HM, Esser H. A comparison of captopril and digoxin in the treatment of patients with mild-to-moderate chronic congestive heart failure. Clin Ther 1995; 17:270-279.
27. Alicandri C, Fariello R, Boni E, Zaninelli A, Muiesan G. Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study. J Cardiovasc Pharmacol 1989; 14 (suppl 8):S77-S82.
28. The German and Austrian Xamoterol Study Group. Double-blind placebo controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet 1988; i:489-493. Patients treated with xamoterol who completed the 3-month therapy had improved exercise duration compared with placebo, but digoxin did not significantly improve exercise performance.
29. Di Bianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R, for The Milrinone Multicenter Trial Group. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989; 320:677-683. Ejection fraction was increased by 1.7% in the digoxin group (P< 0.01) compared with placebo and exercise tolerance was improved in patients treated with digoxin and milrinone compared with placebo.